Cardiomyopathy Tissue Bank in a Cancer Population

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00500734

Enrollment

1000

Registered

2007-07-13

Start date

2002-12-10

Completion date

2020-12-31

Last updated

2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease

Keywords

Cardiomyopathy, Tissue Bank, Heart Disease, Heart Failure, Congestive Heart Failure

Brief summary

Any time the words you, your, I, or me appear, it is meant to apply to the potential participant. The goal of this laboratory research study is to collect and store blood and tissue from patients who have a diagnosis of heart disease and may be at a high risk for the development of heart failure. This blood may be used in the future to identify genes that may play a role in developing congestive heart failure (CHF) from chemotherapy or other sources. This is an investigational study. All will be enrolled at MD Anderson.

Detailed description

You will have a one time blood draw of 2 teaspoons of blood for use in future research. This blood may be studied in the future to try to find possible genetic or biochemical markers that may be the cause of CHF. Your blood will be drawn either on an outpatient basis or during a routine visit to the hospital. If you already have a central line or an IV placed, the blood will be drawn at these sites to decrease the pain and discomfort of the blood draw. The information obtained in this study will not be put into your medical records.

Interventions

PROCEDUREBlood Sample

One time blood draw of 2 teaspoons.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Months to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are at high risk for developing Cardiomyopathy or Congestive Heart Failure. * Patients two months of age and older.

Exclusion criteria

* Those that are not willing to sign an informed consent.

Design outcomes

Primary

Measure	Time frame
Baseline Patient Demographic Information (age, sex, race)	One time visit.
Identification biological markers predisposing cancer patients to development of chemotherapy-induced congestive heart failure	One time visit for collection of blood and tissue samples.

Countries

United States

Contacts

Primary ContactJean-Bernard Durand, MD

jdurand@mdanderson.org713-792-6239

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026